Tags : Initiate

Atriva to Initiate P-II Clinical Study Evaluating ATR-002 for Treatment

Shots: Atriva will commence P-II study assessing ATR-002 vs PBO in hospitalized patients with moderate COVID-19, expected to be initiated in July’2020 ATR-002’s MOA inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in its preclinical studies. The dual antiviral and immunomodulatory effect allows the therapy to prevent progression to critical-stage COVID-19 in […]Read More

Eli Lilly and Junshi to Initiate Clinical Trials of COVID-19

Shots: The companies plan to file IND submission and initiate human clinical studies to evaluate neutralizing mAbs against COVID-19 in the US and China in Q2’2020 The article is being published in Nature, reports the identification and characterization of two mAb’s CA1 and CB6 from the COVID-19 recovered patients CA1 and CB6 mAb’s have demonstrated […]Read More

CoVIg-19 Plasma Alliance to Initiate Clinical Study Evaluating Hyperimmune Therapy

Shots: Shots: Takeda, CSL and NIH’s, CoVIg-19 Plasma Alliance has expanded membership and CT collaborations with >10 plasma and non-plasma companies globally to develop a plasma-derived hyperimmune globulin therapy against COVID-19 The news member to the program includes ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. All the organization will provide specialist advisory expertise, technical […]Read More

Moderna to Initiate P-II Study of mRNA-1273 Against Novel COVID-19

Shots: Moderna has submitted the IND to the US FDA to evaluate its mRNA vaccine candidate (mRNA-1273) in a P-II and late-stage studies upon IND acceptance and safety data from the P-I study led by NIH. Moderna has received FDA’s initial feedback on the design of planned P-II study with its anticipated initiation in Q2’20. […]Read More

AstraZeneca and Saint Luke’s Mid America Heart Institute to Initiate

Shots:Shots: AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated P-III study to assess Farxiga (dapagliflozin) + SOC vs PBO in patients hospitalized with COVID-19 having a risk of developing serious complications like organ failure The primary outcome of the study is time to the first occurrence of death from any cause or new/worsened […]Read More

Novavax Signs a Clinical Trial Agreement with Nucleus Network to

Shots: Novavax deploys expertise of the Nucleus to commence P-I clinical study assessing NVX-CoV2373 for the first confirmed COVID-19 vaccines study outside the US. The P-I study is expected to be initiated in mid-May with its preliminary immunogenicity and safety results in July The study will be the third confirmed global COVID-19 vaccine trial and […]Read More